Fool.com Headlines: Can Vertex Survive Post-Incivek?

Fool.com Headlines Fool.com Headlines

Free Bestselling eBooks Free national bestsellers for your eReader - Fiction, Nonfiction & more! Join 1.5 million book lovers now. Sign-up in under 10 seconds to get the free daily email. From our sponsors

Can Vertex Survive Post-Incivek? Nov 3rd 2013, 14:02, by Todd Campbell, The Motley Fool Gilead Sciences and Johnson & Johnson are about to launch new oral hepatitis C treatments that will significantly reduce Vertex sales from Incivek. The company hopes drugs treating cystic fibrosis can return it to growth.

You are receiving this email because you subscribed to this feed at blogtrottr.com. If you no longer wish to receive these emails, you can unsubscribe from this feed, or manage all your subscriptions